208 related articles for article (PubMed ID: 2735236)
1. [Local immunotherapy with streptococcal preparation, OK-432 in superficial bladder tumors, and common antigens between OK-432 and the tumor].
Fujioka T; Shiraishi M; Tanji S; Koike H; Suzuki K; Kumagai K; Aoki H; Sakuma Y; Ohhori T; Kubo T
Hinyokika Kiyo; 1989 Feb; 35(2):253-7. PubMed ID: 2735236
[TBL] [Abstract][Full Text] [Related]
2. Antigenic relationship between streptococcal preparation OK-432 and tumors and its effect on immunotherapy with OK-432 in patients with superficial bladder tumor.
Fujioka T; Aoki H; Yoshida M; Ohhori T; Kubo T
Urol Int; 1989; 44(4):198-204. PubMed ID: 2477930
[TBL] [Abstract][Full Text] [Related]
3. [An experience of OK-432 intradermal administration in superficial bladder tumors].
Tsujihashi H; Akiyama T; Kurita T; Iguchi M; Uejima S; Kataoka K; Minakata S; Kitagawa M; Sangen H
Hinyokika Kiyo; 1988 Dec; 34(12):2111-4. PubMed ID: 3239522
[TBL] [Abstract][Full Text] [Related]
4. [A randomized controlled study to compare bladder instillation therapy of anticancer agents and combination therapy with OK-432 injection in prevention of post-TUR recurrence of bladder cancer].
Nishio S; Yoshihara H; Yamamoto K; Kishimoto T; Maekawa M
Hinyokika Kiyo; 1988 Nov; 34(11):2053-7. PubMed ID: 2468266
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of streptococcal preparation (OK-432) local injection in patients with urinary bladder carcinoma.
Nishio S; Izeki T; Wada S; Morikawa Y; Yasumoto R; Maekawa M
Osaka City Med J; 1980; 26(1):47-59. PubMed ID: 7267092
[No Abstract] [Full Text] [Related]
6. Splenectomy abolishes antitumor effect of immunotherapy with streptococcal preparation, OK-432, on mouse liver tumors.
Imai S; Nio Y; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Kawabata K; Masai Y; Tobe T
Anticancer Res; 1991; 11(3):1269-74. PubMed ID: 1888159
[TBL] [Abstract][Full Text] [Related]
7. [Local immunotherapy with OK-432 for malignant gliomas--immunohistochemical analysis of chronological changes of tumor tissues].
Saito T; Tanaka R; Sekiguchi K; Yoshida S; Washiyama K; Yamada N; Takeda N
No To Shinkei; 1988 Jul; 40(7):609-15. PubMed ID: 3224036
[TBL] [Abstract][Full Text] [Related]
8. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
9. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.
Vinzenz K; Matejka M; Watzek G; Porteder H; Neuhold N; Micksche M
Cancer Detect Prev Suppl; 1987; 1():463-75. PubMed ID: 3480060
[TBL] [Abstract][Full Text] [Related]
10. The endoscopic intratumor administration of OK-432 in gastric cancer unsuitable for surgery.
Nakazawa S; Yoshino J; Kijima Y; Yasumasa N; Ohhashi S; Mizutani K
Endoscopy; 1989 Jul; 21(4):168-71. PubMed ID: 2776702
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies of the treatment of bladder tumor and its effects--experience in 86 cases].
Sato K; Hatano T; Miyazato T; Saito S; Kashiwabara N; Igarashi M; Koyama Y; Hayakawa M; Osawa A
Hinyokika Kiyo; 1988 Sep; 34(9):1589-92. PubMed ID: 3145682
[TBL] [Abstract][Full Text] [Related]
12. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
13. Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder carcinoma.
Kagawa S; Ogura K; Kurokawa K; Uyama K
J Urol; 1979 Oct; 122(4):467-70. PubMed ID: 480487
[TBL] [Abstract][Full Text] [Related]
14. Histological changes caused by intralesional injection of a streptococcal preparation into bladder cancer.
Fujita K
Cancer Detect Prev; 1988; 11(3-6):397-403. PubMed ID: 3292046
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy of gastric cancer].
Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
[TBL] [Abstract][Full Text] [Related]
16. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
[TBL] [Abstract][Full Text] [Related]
17. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.
Watanabe Y; Iwa T
J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412
[TBL] [Abstract][Full Text] [Related]
19. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical studies on local antitumor effects of streptococcal immunopotentiator, OK-432, in human solid malignant tumors.
Sugenoya A; Usuda N; Adachi W; Kaneko G; Nagata T; Iida F
Arch Pathol Lab Med; 1988 May; 112(5):545-9. PubMed ID: 3282486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
